Retina Vitreous Associates of Florida, St. Petersburg, Florida.
Morsani College of Medicine, University of South Florida, Tampa, Florida.
Retina. 2023 Apr 1;43(4):632-640. doi: 10.1097/IAE.0000000000003699. Epub 2023 Jan 28.
To assess the effect of the total number of fluid-free months after loading on visual and anatomical outcomes in neovascular age-related macular degeneration patients receiving anti-vascular endothelial growth factor therapy.
This post hoc analysis pooled patient-level data from the brolucizumab 6 mg (n = 718) and aflibercept 2 mg (n = 715) arms of the HAWK and HARRIER randomized clinical trials. Based on data from Weeks 12 to 96, patients were assigned to one of five categories based on fluid-free visits (FFVs; the total number of monthly visits at which they were observed to be without retinal fluid). Three definitions of "fluid-free" were explored based on the location of the fluid observed.
Patients allocated to Categories 4 (15-21 FFV) and 5 (22 FFV, always dry) consistently had the best visual and anatomical outcomes at Week 96, whereas patients allocated to Categories 1 (0 FFV, never dry) and 2 (1-7 FFV) consistently had the worst visual and anatomical outcomes. Variability in retinal thickness over time was lowest in Categories 4 and 5.
Absence of retinal fluid at more visits after loading has a positive association with visual and anatomic outcomes in neovascular age-related macular degeneration patients, regardless of fluid type.
评估负荷后无积液月数的总数对接受抗血管内皮生长因子治疗的新生血管性年龄相关性黄斑变性患者的视觉和解剖结局的影响。
本事后分析汇总了 brolucizumab 6mg（n=718）和 aflibercept 2mg（n=715）臂的 HAWK 和 HARRIER 随机临床试验的患者水平数据。根据从第 12 周到第 96 周的数据，根据无积液就诊（FFV；观察到无视网膜积液的每月就诊次数）将患者分为五类。根据观察到的积液位置，探索了三种“无积液”的定义。
在第 96 周时，分配到第 4 类（15-21 次 FFV）和第 5 类（22 次 FFV，始终干燥）的患者始终具有最佳的视觉和解剖结局，而分配到第 1 类（0 次 FFV，从不干燥）和第 2 类（1-7 次 FFV）的患者始终具有最差的视觉和解剖结局。在第 4 类和第 5 类中，视网膜厚度随时间的变化最小。
在负荷后有更多就诊时没有视网膜积液与新生血管性年龄相关性黄斑变性患者的视觉和解剖结局呈正相关，无论积液类型如何。
